Spyre Therapeutics, Inc. Common Stock
$90.41
-$2.27 (-2.45%)
$89.85Day Range$93.34
Key Statistics
Market Cap
$8.17B
Shares Outstanding
88.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 7, 2016
Round Lot
100
Locale
US
Trading Data
Day Open
$92.82
Day High
$93.34
Day Low
$89.85
Volume
501.5K
VWAP
$91.33
Prev Close
$92.68
Transactions
--
Acc. Volume
--
About Spyre Therapeutics, Inc. Common Stock
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
PHARMACEUTICAL PREPARATIONSSIC 2834112 employees221 CRESCENT STREET, WALTHAM, MA, 02453(617) 651-5940IPO Apr 7, 2016US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001636282
- Composite FIGI
- BBG0067L94B2
- Share Class FIGI
- BBG0067L94C1
- Ticker Root
- SYRE
- SIC Code
- 2834
About Spyre Therapeutics, Inc. Common Stock (SYRE) Stock
Spyre Therapeutics, Inc. Common Stock (SYRE) closed the 2026-09-18 session at $90.41, down 2.45% versus the previous close (-2.27). The stock opened at $92.82 and traded between $89.85 and $93.34 during that session. Session trading volume was 501K shares. The volume-weighted average price (VWAP) is $91.33.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Spyre Therapeutics, Inc. Common Stock has a market capitalization of $8.17 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. SYRE is listed on the XNAS exchange. The company employs approximately 112 people. Spyre Therapeutics, Inc. Common Stock is headquartered in WALTHAM, MA. The recorded listing date is 2016-04-07.
On this page you can find market SYRE stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.